Investor Overview

Corporate Profile

Protagonist Therapeutics is a clinical-stage biopharmaceutical company with a proprietary technology platform focused on discovering and developing peptide-based new chemical entities to address significant unmet medical needs. Its primary focus is on developing first-in-class oral peptide drugs that specifically target biological pathways also targeted by currently marketed injectable antibody drugs... Read more

Stock Quote

PTGX (Common Stock)
$10.57 - 0.02 (0.19%)
Exchange :NASDAQ
Volume :17,232
Today's Open$10.81
Previous Close$10.59
Data as of April 21, 2017 4:00 p.m. ET
Refresh quote

Stock Chart

Stock chart for: PTGX.O.  Currently trading at $10.57 with a 52 week high of $26.36 and a 52 week low of $9.93.

Recent Press Releases

April 20, 2017

Protagonist Therapeutics Announces PTG-200 Data Accepted for Oral Presentation at Digestive Diseases Week read more

March 09, 2017

Protagonist Therapeutics to Present at the Oppenheimer & Co. Healthcare Conference read more

March 07, 2017

Protagonist Therapeutics Reports Fourth Quarter and Year-End 2016 Financial Results read more

Upcoming Events


Investor Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.